6‐Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata
Open Access
- 28 May 2020
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 177 (17), 3957-3974
- https://doi.org/10.1111/bph.15145
Abstract
Background and Purpose l‐DOPA‐induced dyskinesia (LID) is considered a major complication in the treatment of Parkinson's disease (PD). Buspirone (5‐HT1A partial agonist) have shown promising results in the treatment of PD and LID, however no 5‐HT‐based treatment has been approved in PD. The present study was aimed to investigate how the substantia nigra pars reticulata (SNr) is affected by buspirone and whether it is a good target to study 5‐HT antidyskinetic treatments. Experimental Approach Buspirone was studied using in vivo single‐unit, electrocorticogram, local field potential recordings along with microdialysis and immunohistochemistry in naïve/sham, 6‐hydroxydopamine (6‐OHDA)‐lesioned or 6‐OHDA‐lesioned and l‐DOPA‐treated (6‐OHDA/l‐DOPA) rats. Key Results Local buspirone inhibited SNr neuron activity in all groups. However, systemic buspirone reduced burst activity in 6‐OHDA‐lesioned rats (with or without l‐DOPA treatment), whereas 8‐OH‐DPAT, a full 5‐HT1A agonist induced larger inhibitory effects in sham animals. Neither buspirone nor 8‐OH‐DPAT markedly modified the low‐frequency oscillatory activity in the SNr or synchronization within the SNr with the cortex. In addition, local perfusion of buspirone increased GABA and glutamate release in the SNr of naïve and 6‐OHDA‐lesioned rats but no effect in 6‐OHDA/l‐DOPA rats. In the 6‐OHDA/l‐DOPA group, increased 5‐HT transporter and decreased 5‐HT1A receptor expression was found. Conclusions and Implications The effects of buspirone in SNr are influenced by dopamine loss and l‐DOPA treatment. The present results suggest that the regulation of burst activity of the SNr induced by DA loss may be a good target to test new drugs for the treatment of PD and LID.Keywords
Funding Information
- Eusko Jaurlaritza (IT747‐13, T747‐13)
- Ministerio de Economía y Competitividad (SAF2016‐77758‐R)
This publication has 77 references indexed in Scilit:
- Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trialBrain, 2013
- Unilateral lesion of the nigrostriatal pathway decreases the response of GABA interneurons in the dorsal raphe nucleus to 5-HT1A receptor stimulation in the ratNeurochemistry International, 2012
- The Role of the Subthalamic Nucleus in L-DOPA Induced Dyskinesia in 6-Hydroxydopamine Lesioned RatsPLOS ONE, 2012
- Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptorsInternational Journal of Neuropsychopharmacology, 2012
- The locus coeruleus Is Directly Implicated in L-DOPA-Induced Dyskinesia in Parkinsonian Rats: An Electrophysiological and Behavioural StudyPLOS ONE, 2011
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Cyclic and Sleep-Like Spontaneous Alternations of Brain State Under Urethane AnaesthesiaPLOS ONE, 2008
- Loss of thalamic serotonin transporters in early drug-naïve Parkinson’s disease patients is associated with tremor: an [123I]β-CIT SPECT studyJournal of Neural Transmission, 2008
- Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disordersArts and The Brain: Psychology and Physiology Beyond Pleasure, 2008
- Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's DiseaseNew England Journal of Medicine, 1988